[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1109085T1 - Νεα αλατα - Google Patents

Νεα αλατα

Info

Publication number
CY1109085T1
CY1109085T1 CY20091100535T CY091100535T CY1109085T1 CY 1109085 T1 CY1109085 T1 CY 1109085T1 CY 20091100535 T CY20091100535 T CY 20091100535T CY 091100535 T CY091100535 T CY 091100535T CY 1109085 T1 CY1109085 T1 CY 1109085T1
Authority
CY
Cyprus
Prior art keywords
salts
new salts
thrombin
alkyl
trypsinoid
Prior art date
Application number
CY20091100535T
Other languages
English (en)
Inventor
Matti Ahlqvist
Martin Bohlin
Tord Inghardt
Anita Lundblad
Carl-Gustaf Sigfridsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1109085T1 publication Critical patent/CY1109085T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Παρέχονται φαρμακευτικά αποδεκτά άλατα πρόσθεσης οξέος ενώσεων του τύπου (I), όπου το R1 αντιπροσωπεύει C1-2αλκυλ υποκατεστημένο από έναν ή περισσότερους υποκατάστατες φθορο˙ το R2 αντιπροσωπεύει C1-2αλκυλ· και το n αντιπροσωπεύει 0, 1 ή 2, τα οποία άλατα είναι χρήσιμα ως προφάρμακα ανταγωνιστικών αναστολέων τρυψινοειδών πρωτεασών, όπως θρομβίνης, και επομένως, συγκεκριμένα, στη θεραπεία παθήσεων όπου απαιτείται αναστολή θρομβίνης.
CY20091100535T 2002-05-31 2009-05-20 Νεα αλατα CY1109085T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201661A SE0201661D0 (sv) 2002-05-31 2002-05-31 New salts
PCT/SE2003/000859 WO2003101957A1 (en) 2002-05-31 2003-05-27 New salts

Publications (1)

Publication Number Publication Date
CY1109085T1 true CY1109085T1 (el) 2012-05-23

Family

ID=20288039

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100535T CY1109085T1 (el) 2002-05-31 2009-05-20 Νεα αλατα

Country Status (31)

Country Link
US (2) US7273858B2 (el)
EP (2) EP2055696A1 (el)
JP (1) JP4541140B2 (el)
KR (1) KR20050009726A (el)
CN (2) CN1656067A (el)
AR (1) AR039937A1 (el)
AT (1) ATE425963T1 (el)
AU (1) AU2003232871B2 (el)
BR (1) BR0311365A (el)
CA (1) CA2487509A1 (el)
CY (1) CY1109085T1 (el)
DE (1) DE60326720D1 (el)
DK (1) DK1513806T3 (el)
ES (1) ES2322048T3 (el)
HK (1) HK1073102A1 (el)
IL (1) IL165295A0 (el)
IS (1) IS7598A (el)
MX (1) MXPA04011912A (el)
MY (1) MY133333A (el)
NO (1) NO329064B1 (el)
NZ (2) NZ554323A (el)
PL (1) PL373794A1 (el)
PT (1) PT1513806E (el)
RU (2) RU2345064C2 (el)
SA (1) SA03240440B1 (el)
SE (1) SE0201661D0 (el)
SI (1) SI1513806T1 (el)
TW (2) TWI367754B (el)
UA (1) UA81246C2 (el)
WO (1) WO2003101957A1 (el)
ZA (1) ZA200409228B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
AU2004318214B2 (en) * 2004-04-09 2007-12-06 Hanmi Holdings Co., Ltd. Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
MXPA06012128A (es) * 2004-04-20 2007-01-31 Sanofi Aventis Sal de clopidogrel y formas polimorfas de la misma.
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
IL77748A (en) 1985-02-04 1991-11-21 Merrell Dow Pharma Amino acid and peptide derivatives as peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (el) * 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
NZ245039A (en) 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
WO1993018060A1 (en) 1992-03-04 1993-09-16 Gyógyszerkutató Intézet Kft. New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (el) * 1992-03-06 1994-05-11 Hoffmann La Roche
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) * 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) * 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
TR199700803T1 (xx) * 1995-02-17 1998-02-21 Basf Aktiengesellschaft Trombin-inhibit�rleri olarak yeni dipeptidik amidinler.
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
AU698911B2 (en) 1995-04-04 1998-11-12 Merck & Co., Inc. Thrombin inhibitors
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
US5863929A (en) * 1996-06-25 1999-01-26 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
SE9603724D0 (sv) 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) * 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) * 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
PT1107791E (pt) 1998-09-04 2007-07-06 Scios Inc Composições de hidrogel para a administração com libertação controlada de factores de crescimento
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
CZ20012529A3 (cs) * 1999-01-13 2001-11-14 Astrazeneca Ab Nový amidinobenzylamidový derivát a jeho pouľití jako inhibitoru thrombinu
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) * 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
DE60135665D1 (de) * 2000-08-16 2008-10-16 Astrazeneca Ab Neue amidino-derivate und deren verwendung als thrombin-inhibitoren
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0102921D0 (sv) * 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) * 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) * 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
EP1513806A1 (en) 2005-03-16
JP2005532346A (ja) 2005-10-27
RU2345064C2 (ru) 2009-01-27
AU2003232871B2 (en) 2010-08-19
AU2003232871A1 (en) 2003-12-19
US20050234035A1 (en) 2005-10-20
US7273858B2 (en) 2007-09-25
UA81246C2 (en) 2007-12-25
IL165295A0 (en) 2005-12-18
KR20050009726A (ko) 2005-01-25
TW200402293A (en) 2004-02-16
NZ554323A (en) 2008-10-31
EP1513806B1 (en) 2009-03-18
NZ536738A (en) 2007-05-31
DK1513806T3 (da) 2009-06-15
MY133333A (en) 2007-11-30
US7763597B2 (en) 2010-07-27
NO20044867L (no) 2004-12-23
CN101735131A (zh) 2010-06-16
ES2322048T3 (es) 2009-06-16
TWI367754B (en) 2012-07-11
IS7598A (is) 2004-12-15
WO2003101957A1 (en) 2003-12-11
AR039937A1 (es) 2005-03-09
MXPA04011912A (es) 2005-03-31
JP4541140B2 (ja) 2010-09-08
NO329064B1 (no) 2010-08-09
HK1073102A1 (en) 2005-09-23
RU2008127541A (ru) 2010-01-20
SI1513806T1 (sl) 2009-06-30
SE0201661D0 (sv) 2002-05-31
SA03240440B1 (ar) 2008-02-24
PT1513806E (pt) 2009-05-04
ATE425963T1 (de) 2009-04-15
EP2055696A1 (en) 2009-05-06
CN1656067A (zh) 2005-08-17
RU2004133388A (ru) 2005-07-10
PL373794A1 (en) 2005-09-19
TW200927094A (en) 2009-07-01
US20080269176A1 (en) 2008-10-30
TWI313173B (en) 2009-08-11
DE60326720D1 (de) 2009-04-30
CA2487509A1 (en) 2003-12-11
BR0311365A (pt) 2005-03-01
ZA200409228B (en) 2005-05-17

Similar Documents

Publication Publication Date Title
CY1109085T1 (el) Νεα αλατα
DK0931788T3 (da) Metalloproteasehæmmere
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CY1113487T1 (el) Νεα παραγωγα μανδελικου οξεος και η χρηση τους ως αναστολεις θροβινης
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
ATE377004T1 (de) Proteinkinaseinhibitoren
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
EA200600509A1 (ru) Соединения пиримидотиофена
ATE457025T1 (de) Kinaseinhibitoren
DE602004031037D1 (de) Heterocyclische inhibitoren von mek
ATE361300T1 (de) Derivate von heteroarylnitrilverbindungen
CY1107149T1 (el) Νεα παραγωγα αμιδινοβενζυλαμινης και χρηση τους ως αναστολεων θρομβινης
EA200300674A1 (ru) Получение гетероциклических сульфонамидных ингибиторов бета-амилоида
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
CY1113171T1 (el) Αντιφλεγμονωδεις παραγοντες
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
PA8589801A1 (es) Aminoalcoxiindoles
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte